Events

ASCO GU 2015

Epic’s collaborators are presenting three studies at the 2015 ASCO Genitourinary Cancers Symposium held in Orlando, Fla., that demonstrate how the Epic Sciences no cell left behind™ platform could be used as a blood test for certain types of metastatic prostate and bladder cancers — liquid biopsies to predict which patients will best respond to certain therapies before they are treated.

Personalized Medicine World Conference 2015

Murali Prahalad, Ph.D., president and CEO, will give a presentation entitled, “CTCs Come of Aage as Biomarkers” at the Personalized Medicine World Conference (PMWC) 2015.

26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Data presented on 1) PD-L1 assay on circulating tumor cells identified in a liquid biopsies from non-small cell lung cancer patients and 2) a new assay for NSCLC biomarkers, including EGFR, KRAS, ALK, MET, RET and ROS1, utilizing both circulating tumor cells (CTC) and circulating free DNA (cfDNA) from a single tube of blood.

ESMO 2014

AACR14: data from Epic's CTC technology in prostate and lung cancer

ASCO GU 2014: Epic and collaborators presents six abstracts

Studies address technical sensitivity, specificity, pharmacodynamics, heterogeneity and patient selection relevant to prostate cancer patient management

Epic Sciences' Research in Prostate Cancer Presented at the 2013 ASCO Genitourinary Cancers Symposium

2H2012 Conferences

1H2012 Conferences

Epic Sciences Presents at 2011 World CTC Summit

For any media inquiries please email [email protected]. Thank you.